Clinical Trials

32 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05673200 2026-04-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06484062 2026-04-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

54 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06802523 2026-04-13

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Suspended

53 enrolled

Phase 1 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07012044 2026-04-13

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

47 enrolled

Leukemia, Myeloid, Acute

NCT06327685 2026-04-01

Avapritinib With Decitabine in Patients With SM-AHN

34 enrolled

Systemic Mastocytosis With an Associated Hematologic Neoplasm

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

22 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT05636514 2026-03-18

CELESTIAL-MDS

12 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04953897 2026-03-10

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

18 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04953910 2026-03-10

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

27 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05403450 2026-02-23

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

33 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT06191978 2026-02-18

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

40 enrolled

Leukemia, Myeloid, Acute

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

18 enrolled

BRCA1 Mutation

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

125 enrolled

Leukemia, Myeloid, Acute

NCT03613532 2025-12-24

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05178693 2025-11-24

LANTana

27 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05037500 2025-11-12

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1 Terminated

8 enrolled

Genitourinary

Prostatic Neoplasms

NCT05396859 2025-10-20

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

13 enrolled

Leukemia, Myeloid, Acute

NCT02998567 2025-08-17

HyPeR

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03813186 2024-08-02

Effect of Food on Blood Levels of ASTX727

Phase 1 Completed

18 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04155580 2024-08-02

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1 Terminated

68 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1 Completed

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05456269 2023-10-03

BISECT

Phase 1 Withdrawn